Skip to main content

Table 2 Posterior probability of non-inferiority for FF/VI versus other relevant ICS/LABA combination therapies*

From: Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy

A
Treatment (mcg) Comparator (mcg) Mean difference, l
(95 % CrI)
Probability of non-inferiority
Margin (l/min)
12 15
FF/VI 92/22 FP/SAL 250/50 2.832 (−12.867–18.531) 97 % 99 %
FF/VI 92/22 BUD/FORM 320/9 0.579 (−15.155–16.312) 94 % 98 %
FF/VI 184/22 FP/SAL 500/50 11.323 (0.289–22.357) >99 % >99 %
FF/VI 184/22 BUD/FORM 640/18 15.136 (−0.943–31.215) >99 % >99 %
B
Treatment Comparator Mean difference, ml
(95 % CrI)
Probability of non-inferiority
Margin (ml)
75 100 125
FF/VI 92/22 FP/SAL 250/50 −36 (−92–19) 92 % 99 % >99 %
FF/VI 92/22 BUD/FORM 320/9 −27 (−98–45) 91 % 98 % >99 %
FF/VI 184/22 FP/SAL 500/50 147 (48–247) >99 % >99 % >99 %
FF/VI 184/22 BUD/FORM 640/18 118 (−19–255) >99 % >99 % >99 %
C
Treatment Comparator Rate ratio
(95 % CrI)
Probability of non-inferiority
Margin (event rate ratio)
10 % 20 %
FF/VI 92/22 FP/SAL 250/50 1.164 (0.428–3.333) 74 % 78 %
FF/VI 92/22 BUD/FORM 320/9 0.985 (0.336–2.574) 82 % 86 %
D
Treatment Comparator Mean difference, units (95 % CrI) Probability of non-inferiority
Margin (units)
0.25 0.5
FF/VI 92/22 FP/SAL 250/50 0.060 (−0.104–0.224) >99 % >99 %
FF/VI 92/22 BUD/FORM 320/9 0.203 (−0.461–0.867) 90 % 96 %
  1. For studies requiring patients to be treated with ICS or ICS/LABA at baseline; full covariate model
  2. *Other relevant ICS/LABA: FP/SAL 250/50 mcg and 500/50 mcg; BUD/FORM 320/9 mcg and 640/18 mcg
  3. a) change from baseline in morning PEF. b) change from baseline in FEV1. c) annual rate of moderate/severe exacerbations. d) AQLQ Total score
  4. Only study length was included as a covariate in analysis of moderate/severe exacerbations data
  5. Note: All stated doses are mcg
  6. AQLQ Asthma quality of life questionnaire, BUD Budesonide, CrI Credible interval, FORM Formoterol, FEV 1 Forced expiratory volume in 1 s, FF Fluticasone furoate, FP Fluticasone propionate, PEF Peak expiratory flow, SAL Salmeterol, VI Vilanterol